In BMSCs, IRS-1 could significantly promote osteogenic differentiation by increasing TAZ expression, which makes IRS-1 a potential therapeutic target for mitigating osteoporosis by stem cell therapy in the near future. The gene discussed is IRS1; the disease is osteoporosis.